medigraphic.com
ISSN 2225-4676 (Electronic)

2022, Number 1

<< Back Next >>

Rev Cubana Neurol Neurocir 2022; 12 (1)

Meningiomatosis in a patient with no family history that conditions the development of the disease

Robles RY, Dueñas OY, León CR

Language: Spanish
References: 26
Page: 1-9
PDF size: 929.90 Kb.


ABSTRACT

Introduction: Meningiomas are tumors that originate from the meninges. These constitute the most common extra-axial intracranial tumors, generally benign and slow growing. Multiple meningiomas are considered when a patient without neurofibromatosis type 2 has more than one meningioma within the central nervous system, regardless of whether they occur simultaneously or separately in time.
Objective: To describe clinical and imaging aspects of meningiomatosis in a patient with no family history that determines the development of the disease.
Case report: This the case of a white female patient, 68 years old, with history of compensated ischemic heart disease and high blood pressure, and no family history of other diseases. Approximately seven months ago, she began to report progressive weakness and instability at walking, with tendency to lateralize to the right. These symptoms were associated with oppressive headache in the right hemicranial zone with no other clinical elements. Simple and contrasted cranial magnetic resonance imaging confirmed the presence of multiple brain meningiomas.
Conclusion: The imaging studies, the age of presentation in the absence of criteria and family history of neurofibromatosis type 2 or another genetic disease that determines the development of meningiomatosis, made it possible to diagnose multiple, probably sporadic, meningiomas in the case reported.


REFERENCES

  1. 1.Lynch J, Sales L, Welling L, Cardoso R. Multiple Intracranial Meningiomas. Diagnosis,biological behavior and treatment. Arq Neuropsiquiatr. 2008;66(3-B):702-7. DOI: 10.1590/s0004-282x2008000500018

  2. 2.Rogers L, Barani I, Chamberlain M, Kaley T, McDermott M, Raizer J, et al. Meningiomas:knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015;122:4-23. DOI: 10.3171/2014.7.JNS131644

  3. 3.Wiemels JL, Wrensh M, Claus EB. Epidemiology and etiology of meningioma. JNeurooncol. 2010;99(3):307-14. DOI: 10.1007/s11060-010-0386-3

  4. 4.Barboza M, Rojas D, Escoe K. Meningiomas múltiples: ¿Qué tan benigna resulta supresencia? J Bras Neurocirurg. 2008 [acceso 19/07/2021];19(1):53

  5. Disponible en: https://jbnc.emnuvens.com.br/jbnc/article/download/659/573 5.Yudoyono F, Sidabutar R, Arifin MZ, Faried A. Multiple meningiomas consisting offibrous meningioma, transitional menigiom, and meningotheliomatous meningioma in one adult patient. Asian J Neurosurg. 2015;10(4):348. DOI: 10.4103/1793-5482.162729

  6. 6.Koech F, Orege J, Ndiangul F, Macharla B, Mbaruku N. Multiple IntracranialMeningiomas: A Review of the Literature and a Case Report. Case Reports Surg. 2013;2013:1-4. DOI: 10.1155/2013/131962

  7. 7.Chaurasia B, Hossain M, Kanti Barua K, Islam Rokib R, Biswas P, Sardar M, et al.Meningiomatosis in non–neurofibromatosis patient: how we dealt with 8 tumors. J Neurol Stroke. 2018;8(6):307-10. DOI: 10.15406/jnsk.2018.08.00335

  8. 8.Djoubairou B, Karekezi C, Moussé N, Doleagbenou A, Gana R, Abbadi N, et al.Méningiome intracrânien multiple: expérience du service de neurochirurgie CHU Avicenne Rabat - Salé, à propos de 4 cas et revue de la literatura. Pan African Med J. 2014;18:204 DOI: 10.11604/pamj.2014.18.204.4811

  9. 9.Jain S, Sundar V, Sharma V, Goel R, Prasanna K. Multiple spinal and cranialmeningiomas: A case report and review of literature. Asian J Neurosurg. 2015;10(2):132-4. DOI:10.4103/1793-5482.145185

  10. 10.Benavides Burbano CA, Díaz Medina JA, Osorio Bohórquez A, Díaz Forero AF, RiverosCastillo WM. Meningiomas Múltiples Intracraneales en ausencia de Neurofiromatosis. Reporte de caso y revisión de la literatura. Rev Chil Neurocirug. 2019;45:264-8. DOI: https://doi.org/10.36593/rev.chil.neurocir.v45i3.147

  11. 11.Lomelí-Ramírez JJ, Rivero-Rejón A, Pérez-Barrera AG, Lomelí-Canavaggio MN.Meningioma múltiple. Caso clínico. Rev Hosp Jua Mex. 2018 [acceso 10/08/2021];85(2):105-9. Disponible en: http://www.medigraphic.com/hospitaljuarez

  12. 12.Juratli TA, Prilop I, Saalfeld FC, Herold S, Meinhardt M, Wenzel C, et al. Sporadicmultiple meningiomas harbor distinct driver mutations. Acta Neuropathol Commun. 2021;9:8. DOI: https://doi.org/10.1186/s40478-020-01113-2

  13. 13.Juratli TA, McCabe D, Nayyar N, Williams EA, Silverman IM, Tummala SS, et al. DMDgenomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018;136:779-92. DOI: https://doi.org/10.1007/s00401-018-1899-7

  14. 14.Smith MJ. Germline and somatic mutations in meningiomas. Cancer Genet.2015;208:107-14. DOI: 10.1016/j.cancergen.2015.02.003

  15. 15.Terrier LM, François P. Meningiomes multiples. Neurochirurgie. 2016;62(3):128-35.DOI: 10.1016/j.neuchi.2015.12.006 16.Parera IC, Báez A, Banfi N, Blumenkrantz Y, Halfon MJ, Barros M, et al. Meningiomasen neurooncología. Neurol Arg. 2016;8(3):210-26. DOI: 10.1016/j.neuchi.2015.12.006

  16. 17.Setia V, Sachdeva D, Odugoudar S, Borde P, Singh D. Rare case of multiplemeningiomas in non-neurofibromatosis patient at unusual locations. Romaniam Neurosurg. 2017 [acceso10/08/2021];31(2):240-3. Disponible en: https://www.journals.lapub.co.uk/index.php/roneurosurgery/article/view/1003

  17. 18.Amelot A, Lemaistre G, Cornu P, Kalamarides M, Peyre M. Multiple meningiomas inpatients with Turner syndrome. Acta Neurochir. 2015;157:621-3. DOI: https://doi.org/10.1007/s00701-015-2360-5

  18. 19.Pereira BJA, de Almeida AN, Paiva WS, de Aguiar PHP, Teixeira MJ, Marie SKN.Natural history of intraventricular meningiomas: systematic review. Neurosurg Rev. 2020;43:513-23. DOI: https://doi.org/10.1007/s10143-018-1019-0

  19. 20.Shamsul A, Kumar ChB, Shalike N. Surgical management of clinoidal meningiomas: 10cases analysis. Neuroimmunol Neuroinflammat. 2018;5:21. DOI: https://doi.org/10.20517/2347-8659.2017.64

  20. 21.Bachir S, Shah S, Shapiro S, Koehler A, Mahammedi A, Samy RN, et al.Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis. Int J Mol Sci. 2021;22:690. DOI: https://doi.org/10.3390/ijms22020690

  21. 22.Smith MJ, Bowers NL, Bulman M, Gokhale C, Wallace AJ, King AT, et al. RevisitingNeurofibromatosis Type 2 Diagnostic Criteria to Exclude LZTR1-Related Schwannomatosis. Neurology. 2017;88(1):87-92. DOI: 10.1212/WNL.0000000000003418

  22. 23.Evans DG, King AT, Bowers NL, Tobi S, Wallace AJ, Perry M, et al. Identifying thedeficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. Genet Med. 2019;21:1525-33. DOI: https://doi.org/10.1136/jmg.2004.023705

  23. 24.Rosser T. Neurocutaneous Disorders. Continuum (Minneap Minn).2018;24(1, ChildNeurology):96-129. DOI: 10.1212/CON.0000000000000562

  24. 25.Tsermoulas G, Turel MK, Wilcox JT. Management of multiple meningiomas. JNeurosurg. 2017;128(5):1403-7. DOI: https://doi.org/10.3171/2017.2.JNS162608

  25. 26.Mansouri A, Guha D, Klironomos G, Larjani S, Zadeh G, Kondziolka D. Stereotacticradiosurgery for intracranial meningiomas: Current concepts and future perspectives. Neurosurgery. 2015;76:362-71. DOI: 10.1227/NEU.0000000000000633

  26. 27.Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical managementof brain tumors and the sequelae of treatment. Neuro Oncol. 2015;17 (4):488-504. DOI: 10.1093/neuonc/nou304




2020     |     www.medigraphic.com